Market Overview

Life Technologies Acquires Pinpoint Genomics and CLIA-Approved Lung Cancer Test

Life Technologies Corporation (NASDAQ: LIFE) today announced the acquisition of Pinpoint Genomics, Inc., and its early-stage non-small cell lung cancer test that can help doctors identify those early-stage patients at high risk for progression to late-stage disease. Lung cancer is currently the leading cause of cancer deaths worldwide, claiming close to 1.5 million lives every year.

Posted-In: News M&A

 

Related Articles (LIFE)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters